TRANSGENE (Euronext Paris: TNG), a biotechnology company designing and developing virus-based immunotherapies against cancers and infectious diseases, has signed a collaborative research agreement with Medesis Pharma with exclusive license options to co-develop an intracellular protein inhibitor that decreases the efficacy of oncolytic viruses.

Medesis Pharma handled the siRNA design, synthesis and formulation in the Aonys® microemulsion. TRANSGENE carried out a first pharmacologic study, enabling it to validate the target gene inhibition and the resulting optimization of the efficacy of its oncolytic viruses.

Share:Share on Facebook
Facebook